|
Volumn 20, Issue 17-18, 2001, Pages 2561-2571
|
Statistical considerations of FDA and CPMP rules for the investigation of new anti-bacterial products
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIINFECTIVE AGENT;
NEW DRUG;
ARTICLE;
CLINICAL RESEARCH;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG SCREENING;
DRUG SURVEILLANCE PROGRAM;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE ORGANIZATION;
HEALTH CARE PLANNING;
HEALTH CARE QUALITY;
HUMAN;
MEDICAL PRACTICE;
PRACTICE GUIDELINE;
QUALITY CONTROL;
STATISTICAL ANALYSIS;
STATISTICAL CONCEPTS;
ANTI-INFECTIVE AGENTS;
CONFIDENCE INTERVALS;
CONTROLLED CLINICAL TRIALS;
EUROPE;
HUMANS;
SAMPLE SIZE;
STATISTICS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 0035884664
PISSN: 02776715
EISSN: None
Source Type: Journal
DOI: 10.1002/sim.729 Document Type: Article |
Times cited : (29)
|
References (18)
|